Recombinant Mouse CD353/SLAMF8 Protein, N-His

Description of Recombinant Mouse CD353/SLAMF8 Protein, N-His

Introduction to Recombinant Mouse CD353/SLAMF8 Protein

Recombinant Mouse CD353/SLAMF8 Protein, also known as Signaling Lymphocytic Activation Molecule Family Member 8 (SLAMF8), is a type I transmembrane protein that belongs to the SLAM family of immune receptors. It is encoded by the SLAMF8 gene and is primarily expressed on the surface of immune cells, such as B cells, T cells, and natural killer (NK) cells.

Structure of Recombinant Mouse CD353/SLAMF8 Protein

Recombinant Mouse CD353/SLAMF8 Protein is a 335 amino acid protein with a predicted molecular weight of approximately 37 kDa. It contains a single extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain consists of an N-terminal IgV-like domain and a C-terminal IgC-like domain, which are connected by a flexible hinge region. The cytoplasmic tail contains several conserved tyrosine residues that serve as potential binding sites for signaling molecules.

Activity of Recombinant Mouse CD353/SLAMF8 Protein

Recombinant Mouse CD353/SLAMF8 Protein is a homophilic receptor, meaning it can interact with other SLAM family members on the surface of neighboring cells. This interaction is mediated by the IgV-like domain of CD353/SLAMF8 and is essential for its signaling function. Upon binding to its ligand, CD353/SLAMF8 can recruit adapter molecules, such as SLAM-associated protein (SAP), to its cytoplasmic tail. This leads to the activation of downstream signaling pathways, including the PI3K-AKT and MAPK pathways, which are involved in cell proliferation, survival, and differentiation.

Application of Recombinant Mouse CD353/SLAMF8 Protein

Recombinant Mouse CD353/SLAMF8 Protein has been widely used in research studies to investigate its role in immune cell signaling and function. It has also been used as an antigen in various in vitro and in vivo assays to study its binding properties and potential therapeutic applications.

One of the main applications of Recombinant Mouse CD353/SLAMF8 Protein is in the study of immune cell activation and regulation. CD353/SLAMF8 has been shown to play a critical role in the activation of B cells, T cells, and NK cells, as well as in the differentiation of T helper cell subsets. It has also been implicated in the regulation of immune cell proliferation and survival.

In addition, Recombinant Mouse CD353/SLAMF8 Protein has been used as an antigen in antibody production and as a target for antibody-based therapies. Antibodies targeting CD353/SLAMF8 have been shown to inhibit the proliferation and survival of cancer cells, making it a potential target for cancer immunotherapy.

Furthermore, Recombinant Mouse CD353/SLAMF8 Protein has been used in the development of diagnostic tools for various diseases. For example, it has been used as a biomarker for the diagnosis and prognosis of B cell lymphoma and chronic lymphocytic leukemia.

Conclusion

Recombinant Mouse CD353/SLAMF8 Protein is a key player in immune cell signaling and function. Its homophilic interaction with other SLAM family members and subsequent activation of downstream signaling pathways make it an important regulator of immune responses. Its diverse applications in research, antibody production, and diagnostics highlight its potential as a therapeutic target for various diseases. Further studies on CD353/SLAMF8 and its interactions with other immune receptors may provide valuable insights into its role in immune regulation and potential therapeutic applications.